For the quarter ending 2026-03-31, LYEL has $350,626K in assets. $76,961K in debts. $90,770K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 90,770 | 60,181 | 123,575 | 98,804 |
| Marketable securities | 163,253 | 187,039 | 196,049 | 177,986 |
| Prepaid expenses and other current assets | 13,281 | 13,719 | 8,577 | 5,424 |
| Total current assets | 267,304 | 260,939 | 328,201 | 282,214 |
| Restricted cash | 1,586 | 1,585 | 1,585 | 1,584 |
| Marketable securities, non-current | 6,954 | 0 | 0 | 20,059 |
| Other investments | 19,000 | 19,000 | 19,000 | 19,000 |
| Property and equipment, net | 32,720 | 34,771 | 36,722 | 39,115 |
| Operating lease right-of-use assets | 17,828 | 18,871 | 19,912 | 20,951 |
| Other non-current assets | 5,234 | 4,886 | 2,545 | 2,530 |
| Total assets | 350,626 | 340,052 | 407,965 | 385,453 |
| Accounts payable | 5,468 | 2,893 | 2,568 | 3,379 |
| Contingent consideration payable | - | 0 | 0 | 5,525 |
| Accrued liabilities and other current liabilities | 31,479 | 46,519 | 29,310 | 27,999 |
| Total current liabilities | 36,947 | 49,412 | 31,878 | 36,903 |
| Operating lease liabilities, non-current | 39,487 | 41,921 | 44,285 | 46,597 |
| Other non-current liabilities | 527 | 517 | 2,681 | 3,030 |
| Total liabilities | 76,961 | 91,850 | 78,844 | 86,530 |
| Common stock, value, issued | 2 | 2 | 2 | 1 |
| Additional paid-in capital | 1,917,379 | 1,867,512 | 1,807,749 | 1,738,850 |
| Accumulated other comprehensive (loss) income | -9 | 242 | 201 | 57 |
| Accumulated deficit | -1,643,707 | -1,619,554 | -1,478,831 | -1,439,985 |
| Total stockholders equity | 273,665 | 248,202 | 329,121 | 298,923 |
| Total liabilities and stockholders equity | 350,626 | 340,052 | 407,965 | 385,453 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)